The FDA has officially ushered in a new era of drug discovery with the approval of Veppanu (vepdegestrant), the first-ever “PROTAC” to reach the market. Developed by Arvinas in partnership with Pfizer, this milestone marks a departure from traditional pharmacology, moving beyond merely blocking disease-causing proteins to completely eliminating them. Harnessing the Cell’s Waste Disposal […]